NCT05415358View on ClinicalTrials.gov

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

September 30, 2035

Study Completion Date

September 30, 2035

Conditions
Lung Cancer, Nonsmall Cell
Interventions
OTHER

Blood and tissue samples

Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of immune checkpoint inhibitor treatment discontinuation.

Trial Locations (2)

27157

RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

28204

RECRUITING

Atrium Health Levine Cancer, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

collaborator

Atrium Health Wake Forest Baptist

OTHER

lead

Wake Forest University Health Sciences

OTHER